Search

Displaying results 3871 - 3880 of 4246 in total
  1. Drug

    Reproterol

    go.drugbank.com/drugs/DB12846
    Investigational

    Reproterol has been used in trials studying the treatment of Asthma, Exercise-Induced.

  2. Drug

    Vadimezan

    go.drugbank.com/drugs/DB06235
    Investigational

  3. Drug

    GC-376 free acid

    go.drugbank.com/drugs/DB15796
    Experimental

    In addition, GC-376 displays potent activity against various coronaviruses such as feline, ferret, and mink M<sup>pro</sup> coronavirus[A219026,A219031,A219036,A219041]. … The compound is known as a direct acting antiviral (DAA) for coronaviruses, and was initially developed using structure-guided design to combat MERS-Cov infections[A219036,A219056].

  4. Drug

    Interferon Gamma

    go.drugbank.com/drugs/DB15753
    Investigational

    Interferon gamma is a Type 1 inflammatory cytokine and the only type II interferon. It has antitumor properties, antiviral activities, and important immunoregulatory functions. The interferon is primarily produced by activated T lymphocy...

  5. Drug

    Hexamethonium

    go.drugbank.com/drugs/DB08960
    Experimental

    A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier.

  6. Drug

    Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences)

    go.drugbank.com/drugs/DB15863
    Experimental

    As of June, 2020, safety and Immunogenicity trials are currently underway for this vaccine (NCT04470609 & NCT04412538).

  7. Drug

    Tefidsogene civaparvovec

    go.drugbank.com/drugs/DB16789
    Investigational

    Tefidsogene civaparvovec, formerly known as SB-913, is an investigational therapy for genome editing.

  8. Drug

    Pam2csk4

    go.drugbank.com/drugs/DB16474
    Investigational

  9. Drug

    Linerixibat

    go.drugbank.com/drugs/DB11729
    ApprovedInvestigational

    Linerixibat is a first-in-class and small-molecule inhibitor of the ileal bile acid transporter (IBAT). On March 19, 2026, linerixibat was approved by the FDA for the treatment of cholestatic pruritus in patients with primary biliary cho...

  10. Drug

    IMC-1C11

    go.drugbank.com/drugs/DB06101
    Experimental

    IMC-1C11 is an anti-angiogenesis agent. It is a chimeric anti-kinase insert domain-containing receptor (KDR) antibody that blocks VEGFR-KDR interaction and inhibits VEGFR-induced endothelial cell proliferation. IMC-1C11 is used for treat...